Ex vivo measurement of B-cell depletion in autoimmune patient samples is essential for assessing drug activity within a physiologically relevant immune context. This approach allows for the evaluation of treatment effects across the full B-cell compartment, including less abundant subsets such as plasmablasts and plasma cells. Identifying residual or treatment-resistant clones contributes to a deeper understanding of therapeutic impact and supports the refinement of dosing strategies and mechanism-of-action studies.

Vivia Biotech has developed a proprietary ex vivo assay to measure B-cell proliferation under native immune conditions. This assay allows for the precise evaluation of how therapeutic agents modulate B-cell expansion, a key process in many autoimmune diseases. Having a reliable method to assess B-cell proliferative activity is essential for understanding drug mechanisms and identifying compounds with the potential to modulate pathogenic immune responses.

A functional tool to assess immune activation and modulation in B- and T-cell–mediated autoimmune responses under native ex vivo conditions.

Measuring immunoglobulin secretion provides a functional readout of B-cell activity, offering insight into their role in autoantibody production and immune dysregulation. This approach is particularly valuable for evaluating the effect of therapeutic agents on antibody-producing cells and for understanding mechanisms involved in disease persistence and treatment resistance.

Comprehensive immunophenotyping of B cells provides detailed insight into the composition and activation state of B-cell compartments in autoimmune disease samples. Identifying and quantifying specific B-cell subsets is essential for understanding disease heterogeneity, monitoring immune dysregulation, and evaluating the impact of therapeutic agents on relevant cellular targets.